No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
Effects of l-carnitine supplement on serum amyloid A and vascular inflammation markers in hemodialysis patients: a randomized controlled trial.
OBJECTIVE We studied the effects of l-carnitine supplement on serum amyloid A ( SAA ) , a systemic inflammation marker , and vascular inflammation markers in hemodialysis patients . DESIGN This was a r and omized , double-blind , placebo-controlled trial . SETTING The study was performed in Soodeh Hemodialysis Center in Islamshahr , Iran . PATIENTS We included 36 hemodialysis patients ( 15 men and 21 women ) . INTERVENTION The patients on hemodialysis were r and omly assigned to either a carnitine or a placebo group . Patients in the carnitine group received 1,000 mg/day oral l-carnitine for 12 weeks , whereas patients in the placebo group received a corresponding placebo during the study . MAIN OUTCOME MEASURES Serum free carnitine , SAA , soluble intercellular adhesion molecule type 1 , soluble intercellular adhesion molecule type 2 , soluble vascular cell adhesion molecule type 1 , sE-selectin , sP-selectin , and oxidized low-density lipoprotein were measured at baseline and at the end of week 12 of the study . RESULTS Mean serum free carnitine concentration increased significantly to 150 % of baseline in the carnitine group at the end of week 12 ( P < .001 ) , whereas serum SAA showed a significant 32 % decrease ( P < .001 ) . No significant changes were observed in the serum concentrations of free carnitine and SAA in the placebo group during the study . There were no significant differences between the two groups in mean changes in serum soluble intercellular adhesion molecule type 1 , soluble intercellular adhesion molecule type 2 , soluble vascular cell adhesion molecule type 1 , sE-selectin , sP-selectin , and oxidized low-density lipoprotein concentrations . CONCLUSION The study indicates that l-carnitine supplement reduces serum SAA , which is a risk factor for cardiovascular diseases in hemodialysis patients , but has no effect on vascular inflammation markers
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .